专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120214831A1 METHOD FOR DETERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT 有权
标题翻译：用于确定抗癌剂敏感性的方法
公开(公告)号：US20120214831A1
公开(公告)日：2012-08-23
申请号：US13504985
申请日：2010-10-29
申请人： Yusuke Tanigawara , Sayo Suzuki , Yusuke Ikoma , Akito Nishimuta , Tetsuya Suzuki , Shinji Sugimoto
发明人： Yusuke Tanigawara , Sayo Suzuki , Yusuke Ikoma , Akito Nishimuta , Tetsuya Suzuki , Shinji Sugimoto
IPC分类号： A61K31/505 , A61P35/00 , A61K31/282 , C40B30/10 , G01N33/53
CPC分类号： A61K31/513 , A61K31/555 , G01N30/7233 , G01N33/574 , G01N33/57419 , G01N2333/4727 , G01N2800/52
摘要： To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker.The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 5,300 to 5,400, a protein or a fragment thereof which is detected as a peak at m/z of 6,130 to 6,230, a protein or a fragment thereof which is detected as a peak at m/z of 7,000 to 7,080, a protein or a fragment thereof which is detected as a peak at m/z of 7,840 to 7,920, a protein or a fragment thereof which is detected as a peak at m/z of 8,920 to 9,000, a protein or a fragment thereof which is detected as a peak at m/z of 12,440 to 12,560, a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, a protein or a fragment thereof which is detected as a peak at m/z of 18,290 to 18,470, a protein or a fragment thereof which is detected as a peak at m/z of 24,660 to 24,750, a protein or a fragment thereof which is detected as a peak at m/z of 35,980 to 36,290, a protein or a fragment thereof which is detected as a peak at m/z of 8,650 to 8,750, a protein or a fragment thereof which is detected as a peak at m/z of 9,100 to 9,200, a protein or a fragment thereof which is detected as a peak at m/z of 11,760 to 11,890, and S100A10, the peaks being determined by means of a mass spectrometer.
摘要翻译：提供用于确定患者对抗癌剂的敏感性的标记物，以及采用该标记物的新型癌症治疗方法。用于确定对抗癌剂的敏感性的标记物由选自蛋白质或其片段的蛋白质或其片段的蛋白质或其片段形成，所述蛋白质或其片段以m / z为峰值检测为5,300至5,400，其蛋白质或其片段被检测为m / z为6,130至6,230的峰，其蛋白质或其片段被检测为m / z为7,000至7,080的峰，其蛋白质或其片段被检测为m / 检测为m / z为8,920至9,000的峰的蛋白质或其片段为7,840至7,920，其蛋白质或其片段被检测为m / z为12,440至12,560的峰，蛋白质或其片段或其片段，其检测为m / z为17,100至17,270的峰，其蛋白质或其片段被检测为m / z为18,290至18,470的峰，其蛋白质或其片段被检测为 m / z的峰值为24,660〜24,750，是以m / z为35,980〜36,290的峰值检测出的蛋白质或其片段，被检测为m / z为8,650〜8,750的峰的ein或其片段，检测为m / z为9,100〜9,200的峰的蛋白质或其片段，检测到的蛋白质或其片段作为m / z为11,760〜11,890的峰，S100A10为峰，通过质谱仪测定。

2. 发明授权

US08765713B2 Method for determination of sensitivity to anti-cancer agent 有权
标题翻译：测定对抗癌剂敏感性的方法
公开(公告)号：US08765713B2
公开(公告)日：2014-07-01
申请号：US13504985
申请日：2010-10-29
申请人： Yusuke Tanigawara , Sayo Suzuki , Yusuke Ikoma , Akito Nishimuta , Tetsuya Suzuki , Shinji Sugimoto
发明人： Yusuke Tanigawara , Sayo Suzuki , Yusuke Ikoma , Akito Nishimuta , Tetsuya Suzuki , Shinji Sugimoto
IPC分类号： A61K31/505 , A61K31/282 , A61P35/00 , C40B30/10 , G01N33/53 , A61K31/513 , G01N33/574 , G01N30/72
CPC分类号： A61K31/513 , A61K31/555 , G01N30/7233 , G01N33/574 , G01N33/57419 , G01N2333/4727 , G01N2800/52
摘要： A marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker, wherein the marker for determining sensitivity to an anti-cancer agent is a protein or a fragment, where in the protein or a fragment thereof exhibits a peak at m/z of 5,300 to 5,400, a peak at m/z of 6,130 to 6,230, a peak at m/z of 7,000 to 7,080 a peak at m/z of 7,840 to 7,920, a peak at m/z of 8,920 to 9,000, a peak at m/z of 12,440 to 12,560, a peak at m/z of 17,100 to 17,270, a peak at m/z of 18,290 to 18,470, a peak at m/z of 24,660 to 24,750, a peak at m/z of 35,980 to 36,290, a peak at m/z of 8,650 to 8,750, a peak at m/z of 9,100 to 9,200, a peak at m/z of 11,760 to 11,890, the peaks being determined by means of a mass spectrometer.
摘要翻译：用于确定患者对抗癌剂的敏感性的标记，以及采用该标记的新型癌症治疗方法，其中用于确定对抗癌剂的敏感性的标记是蛋白质或片段，其中在蛋白质或片段 m / z为5300〜5400，峰/ m为6,130〜6,230，m / z为7,000〜7,080的峰，m / z为7,840〜7,920，峰/ z为8,920至9,000，m / z为12,440至12,560的峰，m / z为17,100至17,270的峰，m / z为18,290至18,470的峰，m / z的峰为24,660至24,750， m / z峰为35,980〜36,290，m / z为8,650〜8,750，峰/峰为9,100〜9,200，峰/峰为11,760〜11,890，峰值为均值的质谱仪。

3. 发明授权

US09459254B2 Method for determining sensitivity to an anticancer agent 有权
标题翻译：确定对抗癌剂敏感性的方法
公开(公告)号：US09459254B2
公开(公告)日：2016-10-04
申请号：US13505143
申请日：2010-10-29
申请人： Yusuke Tanigawara , Sayo Suzuki , Hidehiro Irie , Akito Nishimuta , Tetsuya Suzuki , Shinji Sugimoto
发明人： Yusuke Tanigawara , Sayo Suzuki , Hidehiro Irie , Akito Nishimuta , Tetsuya Suzuki , Shinji Sugimoto
IPC分类号： G01N33/53 , G01N33/574 , A61K31/4745 , A61K31/513 , A61K45/06
CPC分类号： G01N33/574 , A61K31/4745 , A61K31/513 , A61K45/06 , G01N2800/52 , A61K2300/00
摘要： To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker.The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak at m/z of 22,080 to 22,310, and a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, the peaks being determined by means of a mass spectrometer.
摘要翻译：用于确定对抗癌剂的敏感性的标记物由选自蛋白质或其片段的蛋白质或其片段的蛋白质或其片段形成，所述蛋白质或其片段被检测为m / z峰值为16,450至16,620，蛋白质或其片段被检测为m / z为22,080至22,310的峰，以及在m / z为17,100至17,270处被检测为峰的蛋白质或其片段，所述峰通过质谱仪测定。

4. 发明申请

US20120220613A1 METHOD FOR DETERMINING SENSITIVITY TO AN ANTICANCER AGENT 有权
标题翻译：用于确定对抗原剂敏感性的方法
公开(公告)号：US20120220613A1
公开(公告)日：2012-08-30
申请号：US13505143
申请日：2010-10-29
申请人： Yusuke Tanigawara , Sayo Suzuki , Hidehiro Irie , Akito Nishimuta , Tetsuya Suzuki , Shinji Sugimoto
发明人： Yusuke Tanigawara , Sayo Suzuki , Hidehiro Irie , Akito Nishimuta , Tetsuya Suzuki , Shinji Sugimoto
IPC分类号： A61K31/513 , G01N33/574 , A61P35/00 , C07D239/553 , A61K31/4375 , C07D491/22 , G01N27/62 , G01N21/64
CPC分类号： G01N33/574 , A61K31/4745 , A61K31/513 , A61K45/06 , G01N2800/52 , A61K2300/00
摘要： To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker.The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak at m/z of 22,080 to 22,310, and a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, the peaks being determined by means of a mass spectrometer.
摘要翻译：提供用于确定患者对抗癌剂的敏感性的标记物，以及采用该标记物的新型癌症治疗方法。用于确定对抗癌剂的敏感性的标记物由选自蛋白质或其片段的蛋白质或其片段的蛋白质或其片段形成，所述蛋白质或其片段被检测为m / z峰值为16,450至16,620，蛋白质或其片段被检测为m / z为22,080至22,310的峰，以及在m / z为17,100至17,270处被检测为峰的蛋白质或其片段，所述峰通过质谱仪测定。

5. 发明授权

US08809362B2 Anticancer agent sensitivity-determining marker 有权
标题翻译：抗癌剂灵敏度决定标记
公开(公告)号：US08809362B2
公开(公告)日：2014-08-19
申请号：US13505175
申请日：2010-10-29
申请人： Yusuke Tanigawara , Tetsuya Suzuki , Akito Nishimuta , Shinji Sugimoto , Yoshiaki Igarashi
发明人： Yusuke Tanigawara , Tetsuya Suzuki , Akito Nishimuta , Shinji Sugimoto , Yoshiaki Igarashi
IPC分类号： A61K31/4375 , A61P35/00 , A61K31/4745 , G01N33/50 , G01N33/574 , G01N33/18
CPC分类号： A61K31/4745 , G01N33/18 , G01N33/5011 , G01N33/574 , G01N33/6848 , G01N2500/00 , G01N2800/52
摘要： To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker.The marker for determining sensitivity to an anti-cancer agent is formed of one or more substances selected from the group consisting of a substance or a fragment thereof detected as an anion at m/z of 149.05 to 149.06, a substance or a fragment thereof detected as an anion at m/z of 152.99 to 153.00, a substance or a fragment thereof detected as a cation at m/z of 724.34 to 724.35, the peaks being determined by means of a mass spectrometer, glycerol 3-phosphate, dihydrobiopterin, GABA, lactic acid, asparagine, aspartic acid, 2-methylbutyroylcarnitine, 1-methyladenosine, and glutathione, and a substance involved in a metabolic pathway of any of these substances.
摘要翻译：提供用于确定患者对抗癌剂的敏感性的标记物，以及采用该标记物的新型癌症治疗方法。用于确定对抗癌剂的敏感性的标记物由选自以m / z为149.05至149.06作为阴离子检测的物质或其片段的一种或多种物质形成，检测到其物质或片段作为m / z为152.99〜153.00的阴离子，以m / z为724.34〜724.35检测为阳离子的物质或其片段，通过质谱仪，甘油3-磷酸，二氢生物蝶呤，GABA ，乳酸，天冬酰胺，天冬氨酸，2-甲基丁酰基肉碱，1-甲基腺苷和谷胱甘肽，以及涉及任何这些物质的代谢途径的物质。

6. 发明申请

US20120220618A1 ANTICANCER AGENT SENSITIVITY-DETERMINING MARKER 有权
标题翻译： ANTICANCER AGENT敏感性确定标记
公开(公告)号：US20120220618A1
公开(公告)日：2012-08-30
申请号：US13505175
申请日：2010-10-29
申请人： Yusuke Tanigawara , Tetsuya Suzuki , Akito Nishimuta , Shinji Sugimoto , Yoshiaki Igarashi
发明人： Yusuke Tanigawara , Tetsuya Suzuki , Akito Nishimuta , Shinji Sugimoto , Yoshiaki Igarashi
IPC分类号： A61K31/4375 , G01N27/62 , A61P35/00 , C07D491/22
CPC分类号： A61K31/4745 , G01N33/18 , G01N33/5011 , G01N33/574 , G01N33/6848 , G01N2500/00 , G01N2800/52
摘要： To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker.The marker for determining sensitivity to an anti-cancer agent is formed of one or more substances selected from the group consisting of a substance or a fragment thereof detected as an anion at m/z of 149.05 to 149.06, a substance or a fragment thereof detected as an anion at m/z of 152.99 to 153.00, a substance or a fragment thereof detected as a cation at m/z of 724.34 to 724.35, the peaks being determined by means of a mass spectrometer, glycerol 3-phosphate, dihydrobiopterin, GABA, lactic acid, asparagine, aspartic acid, 2-methylbutyroylcarnitine, 1-methyladenosine, and glutathione, and a substance involved in a metabolic pathway of any of these substances.
摘要翻译：提供用于确定患者对抗癌剂的敏感性的标记物，以及采用该标记物的新型癌症治疗方法。用于确定对抗癌剂的敏感性的标记物由选自以m / z为149.05至149.06作为阴离子检测的物质或片段的一种或多种物质形成，检测到其物质或片段作为m / z为152.99〜153.00的阴离子，以m / z为724.34〜724.35检测为阳离子的物质或其片段，通过质谱仪，甘油3-磷酸，二氢生物蝶呤，GABA ，乳酸，天冬酰胺，天冬氨酸，2-甲基丁酰基肉碱，1-甲基腺苷和谷胱甘肽，以及涉及任何这些物质的代谢途径的物质。

7. 发明申请

US20110003842A1 MARKER FOR DETERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT 有权
标题翻译：用于确定抗癌剂敏感性的标记
公开(公告)号：US20110003842A1
公开(公告)日：2011-01-06
申请号：US12865725
申请日：2009-01-30
申请人： Yusuke Tanigawara , Mitsuhiro Watanabe , Eri Arita , Akito Nishimuta , Yasuko Yamayoshi , Takeshi Matsuzaki , Shinji Sugimoto
发明人： Yusuke Tanigawara , Mitsuhiro Watanabe , Eri Arita , Akito Nishimuta , Yasuko Yamayoshi , Takeshi Matsuzaki , Shinji Sugimoto
IPC分类号： A61K31/4375 , C07C229/36 , C07C229/08 , G01N33/68 , A61P35/00
CPC分类号： A61K31/4745 , A61K45/06 , G01N33/5011 , G01N33/6812 , G01N2800/52 , Y10S436/813 , A61K2300/00
摘要： Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.
摘要翻译：提供了用于确定对能够区分各个患者的治疗反应的抗癌剂的敏感性的标记和使用该标记的癌症治疗的新手段。用于确定对抗癌剂的敏感性的标记物含有涉及L-苯丙氨酸和/或N，N-二甲基甘氨酸的代谢途径中的物质。

8. 发明授权

US08945929B2 Marker for determination of sensitivity to anti-cancer agent 有权
标题翻译：测定抗癌药敏感性的标记
公开(公告)号：US08945929B2
公开(公告)日：2015-02-03
申请号：US12865725
申请日：2009-01-30
申请人： Yusuke Tanigawara , Mitsuhiro Watanabe , Eri Arita , Akito Nishimuta , Yasuko Yamayoshi , Takeshi Matsuzaki , Shinji Sugimoto
发明人： Yusuke Tanigawara , Mitsuhiro Watanabe , Eri Arita , Akito Nishimuta , Yasuko Yamayoshi , Takeshi Matsuzaki , Shinji Sugimoto
IPC分类号： G01N33/48 , G01N33/53 , A61K31/4745 , A61K45/06 , G01N33/50 , G01N33/68
CPC分类号： A61K31/4745 , A61K45/06 , G01N33/5011 , G01N33/6812 , G01N2800/52 , Y10S436/813 , A61K2300/00
摘要： Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.
摘要翻译：提供了用于确定对能够区分各个患者的治疗反应的抗癌剂的敏感性的标记和使用该标记的癌症治疗的新手段。用于确定对抗癌剂的敏感性的标记物含有涉及L-苯丙氨酸和/或N，N-二甲基甘氨酸的代谢途径中的物质。

9. 发明授权

US09089540B2 Method for determination of sensitivity to anti-cancer agent 有权
标题翻译：测定对抗癌剂敏感性的方法
公开(公告)号：US09089540B2
公开(公告)日：2015-07-28
申请号：US12865726
申请日：2009-01-30
申请人： Yusuke Tanigawara , Sayo Suzuki , Shinji Sugimoto
发明人： Yusuke Tanigawara , Sayo Suzuki , Shinji Sugimoto
IPC分类号： A61K31/282 , G01N33/574 , A61K45/06 , G01N33/50
CPC分类号： A61K31/282 , A61K45/06 , G01N33/5011 , G01N33/57484 , G01N2333/4727 , G01N2800/52 , A61K2300/00
摘要： Provided are an marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a calcium-binding protein S100A7, S100A8, or S100A10.
摘要翻译：提供了用于确定对能够区分个体患者的治疗反应的抗癌剂的敏感性的标记和使用该标记的癌症治疗的新手段。用于测定对抗癌剂的敏感性的标记物含有钙结合蛋白S100A7，S100A8或S100A10。

10. 发明申请

US20100323034A1 METHOD FOR DETERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT 有权
标题翻译：用于确定抗癌剂敏感性的方法
公开(公告)号：US20100323034A1
公开(公告)日：2010-12-23
申请号：US12865726
申请日：2009-01-30
申请人： Yusuke Tanigawara , Sayo Suzuki , Shinji Sugimoto
发明人： Yusuke Tanigawara , Sayo Suzuki , Shinji Sugimoto
IPC分类号： A61K33/24 , C07K14/00 , G01N33/574 , A61K31/282 , A61K31/4375 , A61P35/00
CPC分类号： A61K31/282 , A61K45/06 , G01N33/5011 , G01N33/57484 , G01N2333/4727 , G01N2800/52 , A61K2300/00
摘要： Provided are an marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a calcium-binding protein S100A7, S100A8, or S100A10.
摘要翻译：提供了用于确定对能够区分个体患者的治疗反应的抗癌剂的敏感性的标记和使用该标记的癌症治疗的新手段。用于测定对抗癌剂的敏感性的标记物含有钙结合蛋白S100A7，S100A8或S100A10。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式